Current pharmaceutical design最新文献_第7页

Click Reaction Inspired Enzyme Inhibitors in Diabetes Care: An Update in the Field of Chronic Metabolic Disorder. 糖尿病护理中的点击反应启发酶抑制剂：慢性代谢紊乱领域的最新进展。

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-10-09 DOI: 10.2174/0113816128310031240923062555

Deeksha Mudgal, Nisha Yadav, Gaurav Kumar Srivastava, Manish Mishra, Vivek Mishra

{"title":"Click Reaction Inspired Enzyme Inhibitors in Diabetes Care: An Update in the Field of Chronic Metabolic Disorder.","authors":"Deeksha Mudgal, Nisha Yadav, Gaurav Kumar Srivastava, Manish Mishra, Vivek Mishra","doi":"10.2174/0113816128310031240923062555","DOIUrl":"https://doi.org/10.2174/0113816128310031240923062555","url":null,"abstract":"Diabetes is a chronic metabolic disorder that impacts all age groups and affects a large population worldwide. Humans receive glucose from almost every food source, and after absorption from the gut, it reaches the liver, which functions as the distribution center for it. The insulin-responsive glucose transporter type 4 (GLUT-4) is a major carrier of glucose to the various cells (majorly expressed in myocytes, adipocytes, and cardiomyocytes) in a well-fed state. In fasting periods, the glucose supply is maintained by glycogenolysis and gluconeogenesis. In diabetes, the distribution of glucose is hampered due to several reasons. Furthermore, to treat this disorder, several drugs have been synthesized, and click chemistry plays an important role. A more recent concept for producing pharmaceuticals with a click chemistry approach makes any reaction more practical and stereospecific, along with a higher yield of products and a smaller number of by-products. This approach comprises a compiled study of the activity of numerous compelling antidiabetic drugs containing 1, 2, 3-triazole derivatives supported by click chemistry. In this review, we discuss the synthetic antidiabetic drugs made via click chemistry and their commendable role in improving diabetes care.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders. 解码大麻和大麻素对神经系统疾病的治疗潜力。

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-10-09 DOI: 10.2174/0113816128318194240918113954

Mayur B Kale, Mohit D Umare, Nitu L Wankhede, Rohitas Deshmukh, Vikrant Abbot, Md Khalid Anwer, Brijesh G Taksande, Aman B Upaganlawar, Milind J Umekar, Seema Ramniwas, Monica Gulati, Rashmi Arora, Tapan Behl

{"title":"Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders.","authors":"Mayur B Kale, Mohit D Umare, Nitu L Wankhede, Rohitas Deshmukh, Vikrant Abbot, Md Khalid Anwer, Brijesh G Taksande, Aman B Upaganlawar, Milind J Umekar, Seema Ramniwas, Monica Gulati, Rashmi Arora, Tapan Behl","doi":"10.2174/0113816128318194240918113954","DOIUrl":"https://doi.org/10.2174/0113816128318194240918113954","url":null,"abstract":"For millennia, Cannabis sativa has served diverse roles, from medicinal applications to recreational use. Despite its extensive historical use, only a fraction of its components have been explored until recent times. The therapeutic potential of Cannabis and its constituents has garnered attention, with suggestions for treating various conditions such as Parkinson's disease, epilepsy, Alzheimer's disease, and other Neurological disorders. Recent research, particularly on animal experimental models, has unveiled the neuroprotective properties of cannabis. This neuroprotective effect is orchestrated through numerous G protein-coupled receptors (GPCRs) and the two cannabinoid receptors, CB1 and CB2. While the capacity of cannabinoids to safeguard neurons is evident, a significant challenge lies in determining the optimal cannabinoid receptor agonist and its application in clinical trials. The intricate interplay of cannabinoids with the endocannabinoid system, involving CB1 and CB2 receptors, underscores the need for precise understanding and targeted approaches. Unravelling the molecular intricacies of this interaction is vital to harness the therapeutic potential of cannabinoids effectively. As the exploration of cannabis components accelerates, there is a growing awareness of the need for nuanced strategies in utilizing cannabinoid receptor agonists in clinical settings. The evolving landscape of cannabis research presents exciting possibilities for developing targeted interventions that capitalize on the neuroprotective benefits of cannabinoids while navigating the complexities of receptor specificity and clinical applicability.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

125 Years of Aspirin: Status of Analytical Methods. 阿司匹林 125 年：分析方法的现状。

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-10-08 DOI: 10.2174/0113816128333651240918064132

Natália Sabina Dos Santos Galvão, Aline Sinzervinch, Isadora Alves Lustosa, Ana Carolina Kogawa

{"title":"125 Years of Aspirin: Status of Analytical Methods.","authors":"Natália Sabina Dos Santos Galvão, Aline Sinzervinch, Isadora Alves Lustosa, Ana Carolina Kogawa","doi":"10.2174/0113816128333651240918064132","DOIUrl":"https://doi.org/10.2174/0113816128333651240918064132","url":null,"abstract":"Aspirin, an analgesic, antipyretic and non-steroidal anti-inflammatory drug, was a fascinating discovery that became the precursor to one of the oldest pharmaceutical success stories. It was discovered in 1899 by Felix Hoffman and patented in 1900. In 2024, Aspirin turns 125 years old and is still one of the bestselling medicines today. This review aims to celebrate 125 years of Aspirin and show the status of analytical methods available in the literature to evaluate pharmaceutical products based on Acetylsalicylic Acid (ASA). In addition, it contextualizes them with the current needs of green and clean analytical chemistry. ASA, despite being consolidated in the consumer market, embraces continuous improvement as it is a fundamental part of studies for other new purposes and studies with associations with other active ingredients. In the manuscripts available in the literature, ASA is predominantly evaluated by HPLC (41%) and UV-Vis (41%) methods, which use methanol (21.82%) and acetonitrile (18.18%), followed by buffer (16.36%). The most evaluated pharmaceutical matrix is ASA tablets (40%), followed by ASA tablets in combination with other drugs (26%). While ASA continues to innovate in the market through new forms of delivery and combinations, as well as intended purposes, the analytical methods for evaluating its pharmaceutical products do not. They continue with non-eco-efficient analytical options, which can significantly improve and meet the current demand for green and sustainable analytical chemistry.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biocompatible Natural Polymers and Cutting-Edge Fabrication Techniques in the Development of Next-Generation Oral Thin Films for Enhanced Drug Delivery Systems. 生物相容性天然聚合物和尖端制造技术在开发新一代强化给药系统口腔薄膜中的应用。

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-10-08 DOI: 10.2174/0113816128329293241001090601

Siddhi Wargantiwar, Sankha Bhattacharya

{"title":"Biocompatible Natural Polymers and Cutting-Edge Fabrication Techniques in the Development of Next-Generation Oral Thin Films for Enhanced Drug Delivery Systems.","authors":"Siddhi Wargantiwar, Sankha Bhattacharya","doi":"10.2174/0113816128329293241001090601","DOIUrl":"https://doi.org/10.2174/0113816128329293241001090601","url":null,"abstract":"Oral thin films are changing the way drugs are delivered, making drug administration more convenient and patient-friendly. This review delves into the fascinating possibilities of natural polymers in thin film design. We consider the benefits of biocompatible polymers produced from chitosan, gelatin, and pullulan. Their intrinsic biodegradability and safety make them excellent for use with a wide range of patients. Additionally, the research investigates novel strategies for creating these distinctive drug delivery systems. We look beyond standard solvent casting techniques, hot melt extrusion methods, rolling methods, etc. These technologies provide exact control over film qualities, allowing for tailored medication delivery and increased patient compliance. This review seeks to bridge the gap between natural polymers and cutting-edge fabrication processes. By investigating this combination, we pave the road for the development of next-generation oral thin films that are more efficacious, patient-acceptable, and environmentally-friendly.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the Therapeutic Efficacy of Lactobacillus Strains in the Management of Ulcerative Colitis: An Overview of Recent Advances. 评估乳酸杆菌菌株在治疗溃疡性结肠炎中的疗效：最新进展概述。

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-10-08 DOI: 10.2174/0113816128322653240925115114

Shaghayegh Rezaei, Elnaz Ghorbani, Abdulridha Mohammed Al-Asady, Amir Avan, Saman Soleimanpour, Majid Khazaei, Seyed Mahdi Hassanian

{"title":"Evaluating the Therapeutic Efficacy of Lactobacillus Strains in the Management of Ulcerative Colitis: An Overview of Recent Advances.","authors":"Shaghayegh Rezaei, Elnaz Ghorbani, Abdulridha Mohammed Al-Asady, Amir Avan, Saman Soleimanpour, Majid Khazaei, Seyed Mahdi Hassanian","doi":"10.2174/0113816128322653240925115114","DOIUrl":"https://doi.org/10.2174/0113816128322653240925115114","url":null,"abstract":"Ulcerative Colitis (UC) known as a sub-category of Inflammatory Bowel Diseases (IBD) is a longterm condition that causes inflammation, irritation, and ulcers in the colon and rectum. Though the precise pathogenesis of UC is not fully understood yet, impaired immune responses and imbalanced intestinal microbiome composition have been regarded as two main key players in colitis pathobiology. As conventional treatments are challenged with limitations and side effects, finding a new therapeutic approach has gained increasing attention. Probiotic bacteria with multifunctional health-promoting properties have been considered novel therapeutic options. There is strong evidence indicating that probiotics exert their therapeutic effects mostly by regulating immune system responses and restoring gut microbiome homeostasis. These results validate the rationale behind the clinical application of probiotics in UC management whether prescribed alone or in combination with conventional therapy. This article explores the pathogenesis of UC, concentrating on the influence of immune dysregulation and intestinal microbiome imbalances. Also, it reviews recent in vitro, in vivo, and clinical studies that have demonstrated the efficacy of Lactobacillus species in decreasing UC symptoms by modifying immune responses, restoring gut microbiota balance, and promoting intestinal barrier function.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Homocysteine Blood Levels and Mandatory Folic Acid Fortification in Serbia. 塞尔维亚的同型半胱氨酸血药浓度和强制性叶酸强化剂。

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-10-03 DOI: 10.2174/0113816128326875240916050251

Zorana Vasiljevic, Natasa Zlatic, Dubravka Rajic, Predrag Mitrovic, Mihajlo Viduljevic, Dragan Matic, Milika Asanin, Sanja Stankovic

{"title":"Homocysteine Blood Levels and Mandatory Folic Acid Fortification in Serbia.","authors":"Zorana Vasiljevic, Natasa Zlatic, Dubravka Rajic, Predrag Mitrovic, Mihajlo Viduljevic, Dragan Matic, Milika Asanin, Sanja Stankovic","doi":"10.2174/0113816128326875240916050251","DOIUrl":"https://doi.org/10.2174/0113816128326875240916050251","url":null,"abstract":"Introduction/objective: The current study aims to investigate the blood Hcy levels in patients with CAD and hypertension in Serbia, a country with a high incidence and mortality of both diseases.Methods: The level of Hcy in the Serbian population was assessed in 123 patients with chronic coronary artery disease (CAD) and hypertension. There were 53 patients with chronic CAD and 70 patients with hypertension (HTA), but without CAD.Results: The Hcy levels were high in both groups of patients (the mean Hcy level of 16.0 ± 7.0 μmol/L) without a statistical difference between the patients in the CAD (14.9 ± 7.3 μmol/L) and hypertension (16.7 ± 6.7 μmol/L) groups. Hypercholesterolemia was found in 81% of the patients with CAD and 92.0% of the patients with HTA, as a common concern across both clinical conditions. It was also found that not a single conventional risk factor (diabetes, hypertension, the smoking status, the family history of CAD, and hyperlipidemia) may individually influence Hcy levels. By contrast, the low levels of vitamin B12 may be related to the high levels of Hcy.Conclusion: Given the fact that it is known that various factors interact and influence Hcy levels and associated cardiovascular risks, specific dietary habits, lifestyle and the other Serbia-specific possible factors were done.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design of Novel Imidazole Derivatives as Potential Non-nucleoside Reverse Transcriptase Inhibitors Using Molecular Docking and Dynamics Strategies. 利用分子对接和动力学策略设计新型咪唑衍生物作为潜在的非核苷类逆转录酶抑制剂

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-10-01 DOI: 10.2174/0113816128322984240725055333

Priyanka Chandra, Swastika Ganguly, Pran Kishore Deb, Manik Ghosh

{"title":"Design of Novel Imidazole Derivatives as Potential Non-nucleoside Reverse Transcriptase Inhibitors Using Molecular Docking and Dynamics Strategies.","authors":"Priyanka Chandra, Swastika Ganguly, Pran Kishore Deb, Manik Ghosh","doi":"10.2174/0113816128322984240725055333","DOIUrl":"https://doi.org/10.2174/0113816128322984240725055333","url":null,"abstract":"Human Immunodeficiency Virus (HIV) has become an epidemic causing Acquired Immunodeficiency Syndrome (AIDS). Highly active antiretroviral therapy (HAART) consists of Nucleoside Reverse Transcriptase Inhibitors (NRTIS), Nucleotide Reverse Transcriptase Inhibitors (NtRTIS), and Non- Nucleoside Reverse Transcriptase Inhibitors (NNRTIS) with HIV Protease Inhibitors (HIV PIs). However, the emergence of resistant strains of NNRTIS necessitates the search for better HIV-1-RT inhibitors.Methods: In this study, a series of novel imidazoles (SP01-SP30) was designed using molecular docking inside the non-nucleoside inhibitory binding pocket (NNIBP) of the HIV-1-RT (PDB ID-1RT2) using Glide v13.0.137, Autodock Vina, and FlexX v2.1.3. Prime MMGBSA was used to study the free energy of binding of the inhibitors with the target enzyme. Molecular dynamics simulation studies were carried out to discover the dynamic behavior of the protein as well as to unveil the role of the essential amino acids required for the better binding affinity of the inhibitor within the NNIBP of the enzyme. The QikProp software module of Schrodinger and online SwissADME were also used to evaluate the drug-likeliness of these compounds.Results: The imidazole derivative SP08 is predicted to be the most promising design compound that can be considered for further synthetic exploitations to obtain a molecule with the highest therapeutic index against HIV-1-RT.Conclusion: The results of the current study demonstrate the robustness of our in-silico drug design strategy that can be used for the discovery of novel HIV-1-RT inhibitors.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insight into Protein Engineering: From In silico Modelling to In vitro Synthesis. 洞察蛋白质工程：从硅学建模到体外合成。

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-10-01 DOI: 10.2174/0113816128349577240927071706

Anagha Balakrishnan, Saurav K Mishra, John J Georrge

{"title":"Insight into Protein Engineering: From In silico Modelling to In vitro Synthesis.","authors":"Anagha Balakrishnan, Saurav K Mishra, John J Georrge","doi":"10.2174/0113816128349577240927071706","DOIUrl":"https://doi.org/10.2174/0113816128349577240927071706","url":null,"abstract":"Protein engineering alters the polypeptide chain to obtain a novel protein with improved functional properties. This field constantly evolves with advanced in silico tools and techniques to design novel proteins and peptides. Rational incorporating mutations, unnatural amino acids, and post-translational modifications increases the applications of engineered proteins and peptides. It aids in developing drugs with maximum efficacy and minimum side effects. Currently, the engineering of peptides is gaining attention due to their high stability, binding specificity, less immunogenic, and reduced toxicity properties. Engineered peptides are potent candidates for drug development due to their high specificity and low cost of production compared with other biologics, including proteins and antibodies. Therefore, understanding the current perception of designing and engineering peptides with the help of currently available in silico tools is crucial. This review extensively studies various in silico tools available for protein engineering in the prospect of designing peptides as therapeutics, followed by in vitro aspects. Moreover, a discussion on the chemical synthesis and purification of peptides, a case study, and challenges are also incorporated.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Updated Review Summarizing the Pharmaceutical Efficacy of Genistein and its Nanoformulations in Ovarian Carcinoma. 最新综述总结了染料木素及其纳米制剂对卵巢癌的药效。

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-10-01 DOI: 10.2174/0113816128332618240823044548

Pratibha Pandey, Seema Ramniwas, Shivam Pandey, Meenakshi Verma, Rahul Kumar, Sorabh Lakhanpal, Fahad Khan, Mohd Asif Shah

{"title":"An Updated Review Summarizing the Pharmaceutical Efficacy of Genistein and its Nanoformulations in Ovarian Carcinoma.","authors":"Pratibha Pandey, Seema Ramniwas, Shivam Pandey, Meenakshi Verma, Rahul Kumar, Sorabh Lakhanpal, Fahad Khan, Mohd Asif Shah","doi":"10.2174/0113816128332618240823044548","DOIUrl":"https://doi.org/10.2174/0113816128332618240823044548","url":null,"abstract":"Implementing lifestyle interventions as a primary prevention strategy is a cost-effective approach to reducing the occurrence of cancer, which is a significant contributor to illness and death globally. Recent advanced studies have uncovered the crucial role of nutrients in safeguarding women's health and preventing disorders. Genistein is an abundant isoflavonoid found in soybeans. Genistein functions as a chemotherapeutic drug against various forms of cancer, primarily by modifying apoptosis, the cell cycle, and angiogenesis and suppressing metastasis. Furthermore, Genistein has demonstrated diverse outcomes in women, contingent upon their physiological characteristics, such as being in the early or postmenopausal stages. The primary categories of gynecologic cancers are cervical, ovarian, uterine, vaginal, and vulvar cancers. Understanding the precise mechanism by which Genistein acts on ovarian cancer could contribute to the advancement of anti-breast cancer treatments, particularly in situations where no specific targeted therapies are currently known or accessible. Additional investigation into the molecular action of Genistein has the potential to facilitate the development of a plant-derived cancer medication that has fewer harmful effects. This research could also help overcome drug resistance and prevent the occurrence of ovarian cancers.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Withdrawn: Camel FGF21 Protein Enhances FGF21 Signaling and its Targeted Compounds Screening 骆驼 FGF21 蛋白增强 FGF21 信号转导及其靶向化合物筛选

IF 2.6 4区医学

Current pharmaceutical design Pub Date : 2024-09-30 DOI: 10.2174/0113816128332755240912041051

Yuan Gao, Fang Yong, Wangye Ji, Lili Zhang, Jibao Hou, Ruilin Ma, Shuqin Zhao, Huizhen Ge, Xiaoyu Wu

{"title":"Withdrawn: Camel FGF21 Protein Enhances FGF21 Signaling and its Targeted Compounds Screening","authors":"Yuan Gao, Fang Yong, Wangye Ji, Lili Zhang, Jibao Hou, Ruilin Ma, Shuqin Zhao, Huizhen Ge, Xiaoyu Wu","doi":"10.2174/0113816128332755240912041051","DOIUrl":"10.2174/0113816128332755240912041051","url":null,"abstract":"The article has been withdrawn at the request of the author.Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.phpBentham science disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously\u0000submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be\u0000reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article\u0000for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or\u0000fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to\u0000the publishers if and when the article is accepted for publication.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0